Ida has shaped the further development of the Leiden Bio Science Park since 2019. Under her leadership, the Leiden Bio Science Park (LBSP) has been further transformed into an innovation district in the field of drug development and health in recent years. The LBSP is a vibrant and rapidly growing innovation ecosystem, currently consisting of more than 350 organizations with over 22,000 jobs and 21,000 students.
It is this foundation on which the Human Capital Agenda and the Multi-Year Vision and Ambition of the Leiden Bio Science Park were recently established, including an intended growth to 30,000 jobs and the further strengthening of our position at the absolute top of the international LSH campuses.
Building and creating an innovation district requires a long breath and is a very intensive process. The end of 2023 is therefore the right time for Ida to hand over the management and take a step towards a slightly different work-life balance.
The board is very grateful to Ida for her great contribution and will start the procedure for her succession in the coming weeks.
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.